The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients

Abstract Background Deregulation of the apoptotic process underlies the pathogenesis of many cancers, including leukemia, but is also very important for the success of chemotherapy treatment. Therefore, the gene expression profile of main apoptotic factors, such as anti-apoptotic BCL2 (B-cell lymphoma protein 2) and pro-apoptotic BAX (BCL2-associated X), as well as genes involved in the multi-drug resistance (ABCB1), could have significant impact on the prognosis and could be used as targets for specific therapy. Patients and methods We analyzed the expression of BCL2, BAX, and ABCB1 in bone-marrow samples collected at diagnosis from 51 adult patients with acute myeloid leukemia with normal karyotype (AML-NK) using real-time polymerase chain reaction method, and examined their prognostic potential. Results Increased expression of BCL2 (BCL2+) was associated with the presence of chemoresistance (p = 0.024), while patients with low BAX expression were more prone to relapse (p = 0.047). Analysis of the combined effect of BCL2 and BAX expression showed that 87% of patients with BAX/BCL2low status were resistant to therapy (p = 0.044). High expression of ABCB1 was associated with BCL2+ status (p < 0.001), and with absence FLT3-ITD mutations (p = 0.019). Conclusions The present analysis of BCL2, BAX, and ABCB1 gene expression profiles is the first study focusing solely on AML-NK patients. Preliminary results showed that patients with high BCL2 expression are likely to experience resistance to chemotherapy, and may benefit from specific anti-BCL2 treatment. Further investigations conducted on a larger number of patients could elucidate actual prognostic significance of these genes in AML-NK patients.

[1]  B. Ebert,et al.  Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.

[2]  S. Scholl,et al.  Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives , 2021, Cancers.

[3]  R. Fanin,et al.  BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies , 2021, Journal of clinical medicine.

[4]  Pawel Wojciechowski,et al.  Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia , 2021, Cancers.

[5]  R. Stuckey,et al.  BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia , 2020, Diagnostics.

[6]  K. Vermeulen,et al.  Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics , 2020, Journal of clinical medicine.

[7]  Austin E. Gillen,et al.  Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. , 2020, Cancer discovery.

[8]  N. Tosic,et al.  The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients , 2019, International journal of laboratory hematology.

[9]  S. Mustjoki,et al.  Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia , 2019, Haematologica.

[10]  Xiaomei Ma,et al.  Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.

[11]  J. Qian,et al.  BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia , 2019, Diagnostic Pathology.

[12]  C. Dinardo,et al.  Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy , 2019, Therapeutic advances in hematology.

[13]  Wei Zhang,et al.  Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia. , 2018, Oncology letters.

[14]  M. Gottesman,et al.  Revisiting the role of ABC transporters in multidrug-resistant cancer , 2018, Nature Reviews Cancer.

[15]  L. Plank,et al.  Differential mRNA expression of the main apoptotic proteins in normal and malignant cells and its relation to in vitro resistance , 2018, Cancer Cell International.

[16]  T. Shamsi,et al.  Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy? , 2018, Cancer management and research.

[17]  K. Young,et al.  Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. , 2017, Blood reviews.

[18]  B. George,et al.  ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers. , 2017, Pharmacogenomics.

[19]  M. Schmid,et al.  ISCN 2016: An International System for Human Cytogenomic Nomenclature (2016) , 2016 .

[20]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[21]  N. Tosic,et al.  Association of Bax Expression and Bcl2/Bax Ratio with Clinical and Molecular Prognostic Markers in Chronic Lymphocytic Leukemia , 2016, Journal of medical biochemistry.

[22]  D. Reinhardt,et al.  Coexpression of Multiple ABC‐Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia , 2016, Pediatric blood & cancer.

[23]  Bing Xu,et al.  Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome. , 2014, Blood cells, molecules & diseases.

[24]  S. Vishnubhatla,et al.  BAX/BCL2 RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia , 2013, Pediatric blood & cancer.

[25]  V. Spasovski,et al.  Prognostic Impact of NPM1 Mutations in Serbian Adult Patients with Acute Myeloid Leukemia , 2012, Acta Haematologica.

[26]  O. Legrand,et al.  Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC , 2012, Haematologica.

[27]  M. Gottesman,et al.  Drug resistance: still a daunting challenge to the successful treatment of AML. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[28]  A. Scorilas,et al.  The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias , 2011, Advances in hematology.

[29]  E. Jacquet,et al.  ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients , 2011, Haematologica.

[30]  A. Órfão,et al.  Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10 , 2011, Leukemia.

[31]  F. Lo Coco,et al.  The genotype nucleophosmin mutated and FLT3‐ITD negative is characterized by high bax/bcl‐2 ratio and favourable outcome in acute myeloid leukaemia , 2010, British journal of haematology.

[32]  V. P. Savitski,et al.  ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells , 2009, Hematology.

[33]  F. Russel,et al.  The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ Regeneration , 2009, Journal of Pharmacology and Experimental Therapeutics.

[34]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[35]  V. P. Savitski,et al.  CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34− cells in childhood AML , 2008, Annals of Hematology.

[36]  Xiaofang Wang,et al.  Simultaneous suppression of multidrug resistance and antiapoptotic cellular defense induces apoptosis in chemoresistant human acute myeloid leukemia cells. , 2007, Leukemia research.

[37]  P. Sonneveld,et al.  CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age , 2007, Annals of Hematology.

[38]  N. Casadevall,et al.  Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality in 171 Patients with Acute Myeloid Leukemia , 2006, Clinical Cancer Research.

[39]  G. Ehninger,et al.  MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia , 2005, British journal of haematology.

[40]  F. Morabito,et al.  Significant co‐expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis , 2004, European journal of haematology.

[41]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Venditti,et al.  Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). , 2003, Blood.

[43]  D. Steinbach,et al.  Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML , 2003, Leukemia.

[44]  N. Russell,et al.  P-glycoprotein in Acute Myeloid Leukaemia: Therapeutic Implications of its Association With Both a Multidrug-resistant and an Apoptosis-resistant Phenotype , 2002, Leukemia & lymphoma.

[45]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[46]  M. McMullin,et al.  High bax expression is a good prognostic indicator in acute myeloid leukaemia. , 2000 .

[47]  John Calvin Reed,et al.  Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid , 1999, Leukemia.

[48]  T. de Witte,et al.  Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance. , 1999, Blood.

[49]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[50]  S. Korsmeyer.  BCL-2 gene family and the regulation of programmed cell death. , 1995, Cancer research.

[51]  K Ueda,et al.  Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. , 1990, The Journal of biological chemistry.

[52]  J. Endicott,et al.  Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance , 1986, Nature.

[53]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[54]  M. Dabrowska,et al.  The rate of apoptosis and expression of Bcl-2 and Bax in leukocytes of acute myeloblastic leukemia patients. , 2003, Neoplasma.

[55]  D. Hasenclever,et al.  High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML) , 2002, Leukemia.

[56]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.